|Genfit SA -- USA Stock|| |
USD 30.78 1.40 4.77%
Chief Financial and Admin. Officer and Member of The Executive Board
Ms. Nathalie Huitorel has served as Executive Vice President of Finance and Member of the Management Board of Genfit SA since July 3, 2008. She previously served as Financial and Administrative Director of the Company from October 2007 to July 3, 2008. She has previously worked in multiple operational functions in technology based companies. For the past 10 years, she had been Financial Director of MS COMPOSITES. Prior to that, she was involved in the listing process of FINUCHEM on the stock market and has led various mergers and acquisitions. She is a graduate of Ecole Superieure de Commerce de Lille.
Age: 55 Executive Since 2008
33 3 20 16 40 00 http://www.genfit.com
The company has return on total asset (ROA)
of (21.4) %
which means that it has lost $21.4 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (41.34) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 10.6 M in total debt with debt to equity ratio (D/E) of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Genfit SA has Current Ratio of 7.18 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver worldwide. Genfit SA was founded in 1999 and is headquartered in Loos, France. Genfit SA is traded on OTC Market in USA.Genfit SA (GNFTF) is traded on OTC Market in USA. It is located in Parc Eurasant? and employs 120 people.